$IBO don’t ever shy out from attaining peaks in the market and delivering unimaginable profit to the shareholders, the shares are trading yesterday with a massive spike of 10% at $0.0500 with sizeable ascent
UI's common shares have been listed for trading on the Frankfurt Stock Exchange, or Bourse Frankfurt, under the ticker symbol "JC4". In Canada, UI will continue to trade on the TSX Venture Exchange under the ticker IBO and on the OTCQB under the ticker symbol IBOGF.
$IBO is one of the handpicked penny stocks in the market today and is racing ahead with full speed, the stock’s financial figures are pretty neat and is expected achieve great heights in the days to come, shares are trading yesterday at $0.0500 with a distinctive spike
UI CEO made a statement "Our capital markets and investor relations strategy includes the FSE listing. We recently began trading on the OTCQB Exchange in the United States, and curiosity in the UI story is growing in Europe, particularly Germany. With a mushrooming market and interest in psychedelic medications, Germany has a reputation for innovation and leadership."
$IBO may be a pretty good stock to carry considering its high yielding capability and mounting optimistic candles within the momentum graph, the stock has delivered a lot of harvest and is presently commercialism at $0.05
Universal Ibogaine Inc. is an expanding Canadian-holding company with an average volume of $145K+ in the last 3 months. The average volume of the company in the last 10 days is $112K with $190.74M share outstanding. The stock price when the market opened was $0.05
"We are happy to have access to Blue Digital's distribution channels, as their range across borders will broaden awareness of our business to new audiences," said Nick Karos, UI's Chief Executive Officer. Because addiction knows no bounds, the remedy we seek must be global in scope." As Blue Digital Media professional radar.
$HMTXF today marked quite an impressive opening in the otc market and is currently trading with a steady pace at $0.1960 with a notable spike
Hemostemix hires new financial advisor to the family
Mr. Rick Groome who has effectively settled 2 securities firm, helping many successful biotechnology companies in providing funds over the last three decades has...
Julie Dumouchel has been named Director of Clinical Trials at UI, which is a significant strategic move. Julie Dumouchel has 25 years of experience in the pharmaceutical sector, where she has worked in a variety of clinical research jobs and has a thorough grasp of the drug development process.
Universal Ibogaine Inc. is an expanding Canadian-holding company with an average volume of 138 K+ in the last 50 days . The average volume of the company in the last 10 days is $88.98K with $190.74M share outstanding. The stock price when the market opened was $0.05
"H.C. Wainwright is a leader in the field and may be a significant strategic partner in our ongoing corporate finance roadmap," said Nick Karos, CEO of Universal Ibogaine. Another crucial step in raising awareness of our brand and service is the chance to share our story with this audience.